The severe EPS miss and guidance cuts signal deteriorating fundamentals. Monitor for further reimbursement pressure disclosures and potential litigation developments. The shareholder investigation adds overhang.
Price Chart
Executive Summary
Myriad Genetics' Q2 2026 EPS of -$0.25 missed consensus of -$0.07 by 263.6%, while revenue of $203.8M was in line. The company previously cut full-year revenue guidance by ~$90M and suspended EBITDA guidance, citing reimbursement pressure and higher denials. A shareholder investigation has been announced regarding whether prior guidance was misleading.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.25 missed consensus of -$0.07 (-263.6% miss)
- Revenue of $203.8M was in line with $203.8M consensus
- Full-year 2026 revenue guidance cut from ~$860-880M to $770-790M
- Adjusted EBITDA guidance suspended entirely
- CFO reaffirmed guidance on May 5, 2026, including 68-69% gross margin
- Shareholder investigation launched by SueWallSt regarding potential misleading statements
Financial Impact
Revenue guidance cut by ~$90M at midpoint; EBITDA guidance suspended; EPS miss of -$0.18 vs consensus
Risk Factors
- Further revenue guidance cuts due to reimbursement pressure
- Potential securities class action litigation
- Suspension of EBITDA guidance signals lack of visibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302842105 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.86 $4.01 | ▲ +3.89% | ▲ +1.32% | $4.54 (+17.62%) |
Sep 16, 2026 16d ago | Press Release | $3.86 $4.01 | ▲ +3.89% | ▲ +1.32% | $4.54 (+17.62%) |
Aug 4, 2026 8w ago | Press Release | $3.17 $3.22 | ▼ −1.58% | ▼ −1.68% | $4.54 (−43.22%) |
Jul 30, 2026 9w ago | Press Release | $2.86 $3.26 | ▼ −13.99% | ▼ −10.47% | $4.54 (−58.74%) |
May 27, 2026 18w ago | Press Release | $3.93 $4.31 | ▲ +9.67% | ▲ +8.46% | $4.54 (+15.52%) |
Mar 17, 2026 28w ago | Press Release | $4.64 $4.68 | ▲ +0.86% | ▲ +1.58% | $4.54 (−2.16%) |
Feb 28, 2026 30w ago | Institutional Cluster | $5.01 $4.81 | ▼ −3.99% | ▼ −2.78% | $4.54 (−9.38%) |
Feb 24, 2026 31w ago | S-3 | $4.78 $5.28 | ▲ +10.46% | ▲ +11.56% | $4.54 (−5.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access